EPISODE · Oct 18, 2017 · 10 MIN
053丨肿瘤疫苗从实验室走向市场
from 全球创新260讲
Provenge作为目前唯一获得审批的治疗性肿瘤疫苗,为何没给创始团队带来丰厚回报?它在上市过程中都踩了哪些坑?为何医生们不敢轻易给患者用这个药?创造了Provenge疫苗的Dendreon公司近况如何?今天我们要介绍的,是过去10年间生物医药领域的焦点——Dendreon公司。
Embed this episode
NOW PLAYING
053丨肿瘤疫苗从实验室走向市场
0:00
10:51
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 全球创新260讲?
This episode is 10 minutes long.
When was this 全球创新260讲 episode published?
This episode was published on October 18, 2017.
Can I download this 全球创新260讲 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!